GlioCure SA, a biotechnology company specializing in neuro-oncology, announces the arrival of Dr. Sandrine Courtès, a researcher-entrepreneur dedicated to brain tumors. She will take up the position of Director of Preclinical Development and Intellectual Property as of July 1, 2021.
Sandrine Courtès has seventeen years of experience in biomedical research, including ten years in academic research (including a post-doctoral fellowship at the SCRIPPS Research Institute – CA, USA) and five years in biotechnology companies. In parallel, she also gained seven years of experience in strategic research management (academic consortium, startup, biotech, consulting).
As an expert in cell biology, oncology and small animal pharmacology, she has designed and conducted proof of efficacy and mechanism of action studies, and notably developed a neuro-oncology drug candidate for the company Coral Biome Pharma.
Since 2016 , she has been involved in various entrepreneurial projects as a manager or consultant, which has allowed her to develop a thorough understanding of the factors that influence successful development of a drug candidate (intellectual property, innovation management, quality, fundraising, etc.). Passionate about research valorization, she has kept a strong link with academic research. By joining GlioCure, she brings network and an important expertise for the management of collaborations and outsourced services. Sandrine also has a personal engagement with brain tumor patient associations, and is convinced of the importance of understanding clinical needs at the earliest stages of R&D.
Sandrine Courtès, is a graduate of the Ecole Normale Supérieure de Lyon (MSc) in molecular-cellular biologyoncology, holds a PhD in neuroscience and is completing a Master’s degree in innovation management and entrepreneurship at HEC Paris.
Commenting on her arrival, Dr. Sandrine Courtès said: “Joining GlioCure is the natural evolution of my scientific and personal fight against glioblastoma. I am very excited to be part of this dynamic team, and it will be an honor to lead the pharmacological development of their most advanced drug candidates to the clinic.”
“We are very pleased and proud that Sandrine Courtès has agreed to join our team,” said Louis-Marie Bachelot, President of GlioCure. “Her experience in the management of biotechnology companies and her skills in pharmacology and intellectual property are tremendous assets for the further development of our first products. Sandrine’s arrival will also enable us to increase our capacity to identify new molecules of interest in neuro-oncology.”
The recruitment of Sandrine Courtès follows the recent arrival of Dr. Olivier Meyer as Vice President of Corporate Development, which together reflect the strong ramp-up of the GlioCure team in view of its future Series A financing round and the entry into regulatory preclinical development of its lead drug candidate GC01.
GlioCure is a drug development company specialized in neuro-oncology with the ambition to give hope to patients suffering from glial diseases, and more particularly to patients with brain tumors. Since the end of 2016, GlioCure has acquired the operational capacities and gathered all the skills and knowhow in translational research and pharmaceutical sciences to identify, select and develop new molecules of interest in neuro-oncology until the authorization of the first clinical trials. In particular, GlioCure has initiated the development of GC01, a best-in-class anti-tumor and neuroprotective peptide, benefiting from more than 10 years of academic research, for which the company has exclusive worldwide rights. GC01 is currently in late non-regulatory preclinical development for the treatment of glioblastoma (GBM), the most common and aggressive brain tumor.
More information is available on the website: www.gliocure.com